Robert I Haddad Selected Research

Fatigue

4/2017	Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
5/2015	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert I Haddad Research Topics

Disease

50	Neoplasms (Cancer) 09/2022 - 07/2004
35	Squamous Cell Carcinoma of Head and Neck 01/2022 - 06/2003
29	Head and Neck Neoplasms (Head and Neck Cancer) 09/2022 - 06/2003
8	Deglutition Disorders (Dysphagia) 01/2021 - 06/2006
8	Oropharyngeal Neoplasms 10/2019 - 07/2010
7	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 12/2009
7	Carcinoma (Carcinomatosis) 01/2021 - 12/2011
7	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2019 - 12/2004
6	Thyroid Neoplasms (Thyroid Cancer) 12/2018 - 03/2008
5	Adenoid Cystic Carcinoma (Cylindroma) 01/2022 - 04/2006
5	Pathologic Constriction (Stenosis) 01/2019 - 11/2008
3	Osteoradionecrosis 01/2022 - 12/2008
3	Neutropenia 01/2021 - 10/2007
3	Anaplastic Thyroid Carcinoma 12/2018 - 10/2014
3	medullary Thyroid cancer 10/2013 - 02/2013
3	Esophageal Stenosis (Esophageal Stricture) 08/2011 - 12/2008
2	Nasopharyngeal Carcinoma 09/2022 - 12/2019
2	Salivary Gland Neoplasms (Salivary Gland Cancer) 01/2020 - 07/2015
2	Mucositis 01/2019 - 10/2007
2	Fatigue 04/2017 - 05/2015
2	Exanthema (Rash) 04/2017 - 05/2015
2	Stomatitis 05/2015 - 12/2013
2	Dental Caries (Decay, Dental) 03/2015 - 12/2008
2	Carcinogenesis 10/2014 - 06/2003
2	Xerostomia 08/2011 - 12/2008
2	Pathologic Complete Response 09/2010 - 05/2006
2	Neoplasm Metastasis (Metastasis) 10/2007 - 12/2004
1	Hematologic Neoplasms (Hematological Malignancy) 10/2021
1	Rupture 01/2021
1	Inflammation (Inflammations) 01/2021
1	COVID-19 01/2021
1	Respiratory Insufficiency (Respiratory Failure) 01/2021
1	Epistaxis (Nosebleed) 12/2019
1	Hemorrhage 10/2017
1	Asthenia 04/2017
1	Diarrhea 04/2017
1	Proteinuria 04/2017

Drug/Important Bio-Agent (IBA)

12	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2003
10	Docetaxel (Taxotere)FDA Link 01/2019 - 10/2003
9	Cisplatin (Platino)FDA LinkGeneric 12/2020 - 12/2004
7	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2017
7	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 07/2010
7	Fluorouracil (Carac)FDA LinkGeneric 04/2012 - 12/2004
5	PlatinumIBA 01/2021 - 07/2012
4	CytokinesIBA 01/2018 - 01/2005
4	Cetuximab (Erbitux)FDA Link 01/2018 - 09/2009
3	Pharmaceutical PreparationsIBA 12/2019 - 10/2014
3	AfatinibIBA 01/2019 - 06/2014
3	vandetanib (ZD6474)IBA 12/2014 - 02/2013
3	Biological ProductsIBA 10/2014 - 10/2007
2	NivolumabIBA 01/2022 - 10/2020
2	pembrolizumabIBA 01/2022 - 01/2021
2	RNA (Ribonucleic Acid)IBA 01/2021 - 10/2014
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2021 - 06/2003
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2013
2	Everolimus FDA Link 01/2018 - 10/2014
2	IodineIBA 01/2018 - 12/2014
2	AntibodiesIBA 01/2017 - 07/2004
2	salicylhydroxamic acid (SHAM)IBA 12/2016 - 07/2012
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 01/2005
2	Tyrosine Kinase InhibitorsIBA 05/2015 - 10/2013
2	Methotrexate (Mexate)FDA LinkGeneric 05/2015 - 06/2014
2	ErbB Receptors (EGF Receptor)IBA 11/2012 - 01/2005
2	TubulinIBA 04/2012 - 12/2009
2	Gefitinib (Iressa)FDA Link 03/2008 - 10/2005
1	AutoantigensIBA 08/2022
1	AntigensIBA 08/2022
1	lirilumabIBA 01/2022
1	Tumor Biomarkers (Tumor Markers)IBA 01/2022
1	avelumabIBA 01/2021
1	IpilimumabIBA 10/2020
1	Nuclear Proteins (Protein, Nuclear)IBA 04/2020
1	Androgen Receptors (Androgen Receptor)IBA 01/2020
1	Sucrose (Saccharose)IBA 01/2020
1	AndrogensIBA 01/2020
1	Azacitidine (5 Azacytidine)FDA Link 12/2019
1	cc-486IBA 12/2019
1	cemiplimabIBA 01/2019
1	cixutumumabIBA 01/2018
1	Programmed Cell Death 1 ReceptorIBA 01/2018
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2018
1	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2018
1	lenvatinibIBA 04/2017

Therapy/Procedure

43	Therapeutics 09/2022 - 10/2004
23	Radiotherapy 01/2022 - 08/2005
17	Induction Chemotherapy 01/2016 - 06/2003
15	Chemoradiotherapy 01/2021 - 06/2003
12	Drug Therapy (Chemotherapy) 09/2022 - 06/2003
5	Immunotherapy 08/2022 - 01/2016
4	Neck Dissection (Radical Neck Dissection) 09/2011 - 06/2005
3	Gastrostomy 01/2019 - 09/2011
3	Aftercare (After-Treatment) 01/2017 - 06/2005
3	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2012 - 11/2008
2	Tracheotomy 10/2017 - 02/2010
2	Re-Irradiation 10/2016 - 10/2010
2	Palliative Care (Palliative Therapy) 10/2007 - 10/2005
1	Time-to-Treatment 01/2022
1	Treatment Delay 10/2021
1	Precision Medicine 01/2018
1	Hematopoietic Stem Cell Transplantation 01/2018